Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 122.38

+23.5%

3:21 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tnsaf who wrote (258)	1/13/2010 12:46:59 PM
From: A.J. Mullen	of 276

Illumina at JP Morgan Heaklthcare Conference I thought I listened to this live, but then I saw the 16% jump in price. I hadn’t noted anything so dramatic, so I went back to listen again and made notes. 2009 was a bad year: reagent problem, and stimulus unintended effects – substitution and delay, slow release of funds. Back on track: reagent problem resolved, strong growth of orders and backlog; good results for 4th quarter ,pre-announcing $176 million revenue. Total annual revenue $662M. 8 new array products. Consumer sequencing program launched and San Diego lab approved 20% growth in revenue expected for 2010. No longer giving quarter by quarter estimates. Genotyping costs reduced by factor of 1000 over 8 years. Focusing on the 1000 genome program. Omniexpress 8.4 million markers on a single array just announced – 250% increase in two years. Bovine HD same substrate as omniexpress. 69% increase in Ag business to $91 M dollars annual revenue. Cost to sequence a genome from $1 million in 2007 to $10K now Hiseq 2000 integrating Solexa technology; 2 flow cells, touch-screen interface, remote monitoring. Under $10K for a single human genome. Plug’n’play reagents First customer order for Hiseq 2000. For 128 machines from BGI! First units shipping in Feb. Revenue to be recognized over next three years Improvements in processing the data mean that raw data is processed in more or less realtime, which keeps the data storage manageable. I'm disappointed there wasn't more information on their reasons for selling sequencing direct to the primary consumer. It's a big change to go from selling to big companies and well-supported academics to selling to Joe The Plumber who worries because his second cousin might have had Parkinson's late in life. Ashley (I hold this stock) Wasn’t there an X-prize for this? Or was it for getting the cost per genome down to $1 000?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next